IO生物技术第三阶段：Cylembio Plus KEYTRUDA将一线晚期黑色素瘤的中位无进展期延长至19.4个月，尽管统计学意义上的差距很小，但仍显示出具有临床意义的改善

2025-10-20 14:48

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance
- Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone
Final data from the Phase 2 basket trial in lung and head & neck cancers also presented